Dysplastic Nevus: Surgical Indications & Melanoma Risk

Dermoscopy (dermatoscopy) significantly improves the clinical assessment of dysplastic nevi compared to naked-eye examination alone. Classic dermoscopic features of dysplastic nevi include a reticular pattern (pigment network) that may be irregular or atypical. Characterized by thickened lines, variable mesh sizes, and abrupt termination at the periphery. Central hyperpigmentation or structureless areas of brown or tan pigmentation are common. A multicomponent pattern (combination of reticular, globular, and structureless areas) may be seen, but the presence of a predominantly reticular pattern with gradual fading at the periphery favors a benign dysplastic nevus over melanoma. Dermoscopic features that raise concern for melanoma rather than dysplastic nevus include blue-white structures, regression structures (white scar-like areas, peppering), atypical vascular patterns (dotted vessels, linear-irregular vessels), and a negative pigment network. Sequential digital dermoscopy (monitoring the same lesion over time with standardized photographs) is the most powerful tool for distinguishing stable dysplastic nevi from evolving melanomas. Morphologic change detected on sequential dermoscopy is the strongest indication for biopsy.

Despite the lack of a universally standardized system, most dermatopathology practices grade cytologic atypia on a three-tier scale: mild, moderate, and severe. Mild atypia features slight nuclear enlargement with minimal pleomorphism and preserved nuclear-to-cytoplasmic ratio. The melanocytes are slightly larger than normal but retain a relatively uniform appearance. Moderate atypia shows more pronounced nuclear enlargement, irregular nuclear contours, variably prominent nucleoli, and increased nuclear-to-cytoplasmic ratio. These nevi sit in the ambiguous middle ground and generate the most management controversy. Severe atypia demonstrates marked nuclear enlargement, pronounced pleomorphism, hyperchromatic irregular nuclei, and prominent nucleoli with features that approach but do not meet the diagnostic threshold for melanoma. The distinction between severe dysplasia and melanoma in situ is one of the most challenging diagnoses in dermatopathology. Studies examining interobserver agreement among expert dermatopathologists show only moderate concordance (kappa 0.34-0.50) for the overall diagnosis of dysplastic nevus, and even lower concordance for distinguishing severe dysplasia from melanoma in situ. The WHO classification acknowledges these limitations and notes that "low-grade" (mild) and "high-grade" (moderate-severe) dysplasia is an acceptable binary simplification when three-tier grading is not reliably reproducible.

The most well-characterized genetic alteration underlying FAMM syndrome involves germline mutations in the CDKN2A gene (chromosome 9p21), which encodes two distinct tumor suppressor proteins through alternative splicing: p16INK4a and p14ARF. The p16INK4a protein inhibits cyclin-dependent kinases CDK4 and CDK6, preventing phosphorylation of the retinoblastoma protein and maintaining cell cycle arrest at the G1/S checkpoint. Loss of p16 function allows uncontrolled cell cycle progression, a critical step in melanocyte transformation. CDKN2A mutations are found in approximately 20-40% of melanoma-prone families worldwide, with geographic variation in the prevalence of specific mutations (the p16-Leiden founder mutation in the Netherlands, V126D in the Mediterranean). Less commonly, germline mutations in CDK4 (R24C and R24H), which render the CDK4 protein resistant to p16 inhibition, produce a phenocopy of FAMM syndrome. Additional susceptibility genes include BAP1 (associated with atypical Spitz tumors, uveal melanoma, and mesothelioma), TERT promoter variants, POT1, and MC1R variants (particularly red hair/fair skin variants that modestly increase melanoma risk in the general population but substantially amplify risk in CDKN2A mutation carriers).

Patients with confirmed or suspected FAMM syndrome require intensive lifelong melanoma surveillance. Current expert consensus recommendations include: (1) Total body skin examination every 3-6 months by a dermatologist experienced in pigmented lesion assessment. (2) Baseline total body photography (TBP) with high-resolution images of all body surfaces, updated every 1-2 years, providing an objective comparison standard for detecting new or changing lesions. (3) Sequential digital dermoscopy of individual atypical nevi at 3-6 month intervals. Any morphologic change beyond normal aging-related evolution triggers biopsy. (4) Patient education on self-examination technique with emphasis on the ABCDE criteria and the ugly duckling sign, with instructions to report any changing, new, or symptomatic lesion immediately. (5) Genetic counseling and consideration of germline genetic testing (CDKN2A, CDK4, BAP1) for families meeting criteria. A positive result confirms the diagnosis, guides screening intensity, and enables cascade testing of at-risk relatives. (6) In CDKN2A mutation carriers, consider surveillance for associated cancers, particularly pancreatic cancer (annual pancreatic cancer screening with MRI/MRCP or endoscopic ultrasound may be recommended in high-risk families, as CDKN2A mutations confer a 15-25% lifetime risk of pancreatic cancer).

For mild dysplasia with clear biopsy margins, observation without re-excision is the standard approach. Multiple studies have demonstrated that the risk of melanoma arising at a site of completely excised mildly dysplastic nevus is negligible. For mild dysplasia with positive margins (residual nevus at the biopsy edge), clinical monitoring is generally acceptable given the very low risk, though some practitioners prefer narrow re-excision for completeness. For moderate dysplasia with clear margins, management is the most controversial area. Some experts recommend observation (citing the low absolute risk of transformation), while others recommend re-excision with 2-3mm clinical margins (citing the diagnostic uncertainty inherent in moderate atypia and the desire to ensure complete removal). For moderate dysplasia with positive margins, most experts recommend re-excision with 2-3mm clinical margins to ensure the lesion is completely removed and to exclude a more severe lesion at the deep or peripheral margin that may have been undersampled on biopsy. For severe dysplasia regardless of margin status, the majority consensus is that re-excision should be performed with clinical margins of 2-5mm. Severe dysplasia sits dangerously close to melanoma in situ on the diagnostic spectrum, interobserver agreement at this threshold is poor, and the consequences of underdiagnosis are substantial. Many authorities recommend treating severely dysplastic nevi with the same surgical approach as melanoma in situ (5mm margins) as a precautionary measure.

Mohs micrographic surgery is NOT the standard of care for dysplastic nevi and should not be routinely employed for these lesions. The primary reasons are: (1) dysplastic nevi are benign neoplasms with very low malignant potential, and the tissue-sparing advantage of Mohs is rarely necessary; (2) frozen section interpretation of melanocytic lesions is inherently challenging, and dysplastic nevi may be particularly difficult to assess on frozen sections; (3) distinguishing the peripheral junctional component of a dysplastic nevus from normal melanocytic density on frozen sections can be unreliable. However, there are narrow circumstances where margin-controlled excision may be considered for severely dysplastic nevi: (a) lesions in cosmetically or functionally critical areas (periorbital, nasal tip, lip) where tissue conservation is paramount; (b) large lesions where standard 5mm margins would create a significant defect; (c) recurrent atypical nevi at a previously excised site. In these situations, staged excision with permanent sections and immunohistochemistry (MART-1). Analogous to "slow Mohs" for melanoma in situ. May be preferable to traditional frozen-section Mohs. Standard excision with permanent section processing remains the preferred approach for the vast majority of dysplastic nevi requiring re-excision.

The molecular pathway from normal melanocyte to common nevus to dysplastic nevus to melanoma involves the sequential accumulation of driver mutations and epigenetic alterations. The initiating event in nevogenesis is typically a gain-of-function mutation in the MAPK pathway. BRAF V600E mutations are found in approximately 70-80% of common acquired nevi and 60% of dysplastic nevi, while NRAS mutations (Q61K/R/L) account for most of the remainder. These mutations drive initial melanocyte proliferation but are insufficient for malignant transformation; benign nevi undergo oncogene-induced senescence mediated by p16INK4a and p21 cell cycle arrest, explaining why most nevi remain stable indefinitely. The transition from benign nevus to dysplastic nevus involves partial escape from senescence, potentially through accumulation of additional mutations or epigenetic silencing of tumor suppressor genes. The critical transformation to melanoma requires further genetic hits: loss of CDKN2A/p16 function (through deletion, mutation, or promoter methylation), TERT promoter mutations (enabling telomerase reactivation and cellular immortalization), PTEN loss, and TP53 mutations. This multistep model explains both why dysplastic nevi can remain stable for decades (multiple additional mutations are required for full transformation) and why FAMM patients with germline CDKN2A loss are at dramatically elevated risk (one critical barrier to transformation is already disabled in every melanocyte).

The recommended frequency of dermatologist-performed TBSE varies by risk category. For high-risk patients (FAMM syndrome, personal history of melanoma, >5 clinically atypical nevi, CDKN2A mutation carriers), TBSE should be performed every 3-6 months. For moderate-risk patients (sporadic dysplastic nevi, >50 common nevi, strong family history without FAMM criteria), TBSE every 6-12 months is appropriate. For low-risk patients (isolated dysplastic nevus on biopsy, few nevi, no family history), annual TBSE is generally sufficient, with the understanding that the TBSE also serves a broader skin cancer screening function. These intervals should be adjusted based on the individual patient's history. A patient with a recent melanoma diagnosis or rapidly changing nevi may require more frequent monitoring during the initial period of heightened surveillance.

Sequential digital dermoscopy (SDD) involves capturing standardized dermoscopic images of individual nevi at regular intervals (typically every 3-6 months) and comparing sequential images for morphologic change. Any significant change in dermoscopic features. New structures, loss of symmetry, color changes beyond normal aging-related evolution, architectural disruption. Triggers biopsy regardless of the absolute dermoscopic appearance. SDD has been shown to increase melanoma sensitivity by 20-30% compared to single-time-point dermoscopy and reduces the number of unnecessary biopsies by allowing confident observation of stable lesions. Total body photography provides an overview of all cutaneous lesions at a given time point, enabling detection of new lesions (which account for the majority of melanomas, even in patients with many nevi) and gross changes in existing lesions. Automated total body photography systems with mole-mapping software and AI-assisted change detection are increasingly available and may improve the efficiency and sensitivity of surveillance in high-risk patients.

Biopsy of a pigmented lesion should be performed when clinical or dermoscopic assessment raises concern for melanoma or when monitoring reveals significant change. Specific biopsy indications include: (1) Dermoscopic change on sequential monitoring. This is the most sensitive indication and should have a low threshold. (2) The ugly duckling sign. A nevus that looks clinically different from all of the patient's other nevi, or a nevus in an isolated location without comparator lesions. (3) New symptoms. Itching, pain, bleeding, or tenderness in a previously asymptomatic nevus (though most symptomatic nevi are benign). (4) Rapid growth or evolution. Any pigmented lesion that has changed noticeably over weeks to months. (5) De novo pigmented lesion in an adult >40 years old. New nevi are uncommon after age 40, and a new pigmented lesion in this age group should be viewed with higher suspicion. (6) Clinical ABCDE criteria. A lesion scoring highly across multiple ABCDE parameters. The preferred biopsy technique for a suspected melanocytic lesion is excisional biopsy (narrow-margin excision or deep saucerization shave that captures the full thickness and lateral extent of the lesion), as this provides the pathologist with the complete lesion architecture needed for accurate diagnosis and grading.

Step 1. Establish the histologic grade (mild, moderate, or severe) and margin status (clear or involved). Step 2. For mild atypia: if margins are clear, no further surgical intervention is needed; clinical monitoring is appropriate at a frequency determined by the patient's overall risk profile. If margins are involved, clinical monitoring is acceptable given the extremely low risk, though narrow re-excision (2mm margins) is reasonable if the clinician or patient prefers definitive clearance. Step 3. For moderate atypia: if margins are clear, the decision between observation and re-excision depends on institutional practice and patient risk factors. In patients with FAMM syndrome, personal melanoma history, or severe/moderate atypia on prior biopsies, many experts favor re-excision with 2-3mm margins even when the initial margins are clear, to exclude an undersampled more severe component. If margins are involved, re-excision with 2-3mm margins is recommended by most authorities. Step 4. For severe atypia: re-excision is recommended regardless of margin status. When margins are clear, re-excision with 2-5mm margins confirms the absence of residual atypia or an undersampled melanoma. When margins are involved, re-excision with 5mm margins (equivalent to melanoma in situ approach) is strongly recommended, and expert dermatopathology re-review of the original specimen should be considered. Step 5. Following re-excision, if the re-excision specimen shows clear margins with no residual atypia or downgraded atypia, the patient enters the surveillance pathway based on their overall risk. If the re-excision reveals melanoma in situ or invasive melanoma (an upgrade from the biopsy diagnosis), management transitions to the melanoma treatment algorithm with appropriate margins and consideration of SLNB for invasive disease.

Referral to a melanoma multidisciplinary team (MDT). Typically comprising a dermatologist, surgical oncologist, dermatopathologist, medical oncologist, and radiation oncologist. Should be considered in specific clinical scenarios: (1) Re-excision of a severely dysplastic nevus reveals melanoma in situ or invasive melanoma. The patient now requires melanoma-protocol staging and treatment. (2) Multiple severely dysplastic nevi requiring excision in a patient with suspected FAMM syndrome. Coordinated management planning is beneficial. (3) A dysplastic nevus in a patient with a concurrent or recent melanoma diagnosis. The distinction between a new primary melanoma, a recurrence, and a dysplastic nevus requires expert pathologic and clinical correlation. (4) Diagnostic disagreement between dermatopathologists on a challenging lesion at the severe dysplasia vs. melanoma boundary. MDT discussion may resolve the diagnostic uncertainty. (5) FAMM syndrome kindreds with confirmed CDKN2A mutations. Genetic counseling, pancreatic cancer screening, and coordinated surveillance benefit from MDT oversight.